Telix Pharmaceuticals Limited (TLX)
TLX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/2007191/000162828026009943/0001628280-26-009943-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | TLX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Australia |
| IPO year | Not reported by the screener |
| SEC CIK | 0002007191 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | C3 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $803.8M |
| Net income | -$7.1M |
| Operating income | Not in SEC XBRL data |
| Net margin | -0.9% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4.6× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | DRS | 2024-09-13 |
| Latest annual report | 20-F | 2026-02-20 |
| Latest quarterly / interim | 6-K | 2026-09-30 |
Source: SEC EDGAR submissions feed, 104 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.4% |
| 1 month | -17.1% |
| 3 months | -1.8% |
| Year to date | +42.0% |
| 1 year | +11.5% |
| From 52-week high | -17.1% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TNGX | Tango Therapeutics Inc. | $22.22 | -8.07% | $3.7B |
| OGN | Organon & Co. Common Stock | $13.77 | 0.00% | $3.6B |
| LEGN | Legend Biotech Corporation | $17.88 | +0.45% | $3.5B |
| EWTX | Edgewise Therapeutics Inc. | $36.28 | -5.64% | $3.9B |
| AMLX | Amylyx Pharmaceuticals Inc. | $26.85 | -2.29% | $3.4B |
| ABCL | AbCellera Biologics Inc. Common Shares | $12.61 | -0.20% | $4.1B |
| VKTX | Viking Therapeutics Inc. | $26.65 | -5.96% | $3.3B |
| XENE | Xenon Pharmaceuticals Inc. Common Shares | $34.42 | -3.88% | $3.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier